NCT05903170 Shock Energy for Electrical Cardioversion of Persistent Atrial Fibrillation
| NCT ID | NCT05903170 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wellington Hospital |
| Condition | Atrial Fibrillation |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-08 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2025-08 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to compare the efficacy of a maximum output shock for cardioverting atrial fibrillation between two commonly used defibrillators in New Zealand . These machines have different maximum energy outputs, and to date no head-to-head comparison cardioverting atrial fibrillation between the two has been undertaken. The main question it aims to answer is whether either device is more likely to cardiovert patients referred for atrial fibrillation. Participants will be randomized to undergo cardioversion with one of two defibrillators at either 200J or 360J. Participants in each arm will undergo up to three shocks at the energy-level to which they have been randomized, using a standardized procedure. For participants randomized to the lower energy level who fail to return to normal rhythm after three shocks, they will be given a fourth shock at the higher energy level. All participants will then be asked to undertake a blood test the day following the cardioversion, and receive a follow up phone call. These are to ensure there is no difference in the safety of the procedure between the two energy levels. It is worth noting that these two components of the study (the blood test and phone call) are the only additional time commitment that is expected to be involved if you choose to participate in the study.
Eligibility Criteria
Inclusion Criteria: * Age \>18 * Patients undergoing either elective outpatient or non-emergent inpatient cardioversion for atrial fibrillation * Eligible for anticoagulation * Reliably anticoagulated for ≥three weeks prior to cardioversion, AF onset within 48hrs of cardioversion, or left atrial thrombus excluded on transoesophageal echocardiogram * Able to consent to cardioversion, and study participation Exclusion Criteria: * Contraindication to anticoagulation * Atrial flutter * Emergent cardioversion * Implantable cardiac device (PPM or ICD) * Unable to consent to cardioversion and/or study participation * Pregnancy
Contact & Investigator
Allan Plant, FRACP
PRINCIPAL INVESTIGATOR
Wellington Hospital
Frequently Asked Questions
Who can join the NCT05903170 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05903170 currently recruiting?
Yes, NCT05903170 is actively recruiting participants. Contact the research team at allanmplant@gmail.com for enrollment information.
Where is the NCT05903170 trial being conducted?
This trial is being conducted at Wellington, New Zealand.
Who is sponsoring the NCT05903170 clinical trial?
NCT05903170 is sponsored by Wellington Hospital. The principal investigator is Allan Plant, FRACP at Wellington Hospital. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.